The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma.
 
Harry H. Yoon
Honoraria - Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; BeiGene; BeiGene; BeiGene; BeiGene; LSK Biopharma; LSK Biopharma; LSK Biopharma; LSK Biopharma; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; BeiGene; BeiGene; BeiGene; BeiGene; LSK Biopharma; LSK Biopharma; LSK Biopharma; LSK Biopharma; Macrogenics; Macrogenics; Macrogenics; Macrogenics; Merck; Merck; Merck; Merck
Research Funding - Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Lilly/ImClone (Inst); Lilly/ImClone (Inst); Lilly/ImClone (Inst); Lilly/ImClone (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Lilly; Lilly; Lilly; Lilly
 
Ken Kato
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - BeiGene; BeiGene; BeiGene; BeiGene; MSD; MSD; MSD; MSD; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Research Funding - Beigene (Inst); Beigene (Inst); Beigene (Inst); Beigene (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst)
 
Richard Hubner
Honoraria - Abbott Nutrition; Abbott Nutrition; Abbott Nutrition; Abbott Nutrition; Ipsen; Ipsen; Ipsen; Ipsen
Consulting or Advisory Role - BTG; BTG; BTG; BTG; Eisai; Eisai; Eisai; Eisai; Shire; Shire; Shire; Shire
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Roche; Roche; Roche; Roche
 
Eric Raymond
No Relationships to Disclose
 
Aiyang Tao
Employment - BeiGene; BeiGene; BeiGene; BeiGene
 
Sumei Liu
Employment - BeiGene; BeiGene; BeiGene; BeiGene
 
Ibrahim Qazi
Employment - Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics
Stock and Other Ownership Interests - Exelixis; Exelixis; Exelixis; Exelixis; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics
Travel, Accommodations, Expenses - Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics
 
Jian-Ming Xu
No Relationships to Disclose